Amiodarone reduces the amount of ablation during catheter ablation for persistent atrial fibrillation
Authors:
Open Access
- 19 January 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 16 (7) , 1007-1014
Abstract
The step-wise approach to catheter ablation for persistent atrial fibrillation (AF) requires considerable substrate modification targeting at complex fractionated atrial electrograms (CFAEs) in addition to pulmonary vein (PV) isolation. An alternative strategy that minimizes the amount of ablation would be desirable. The aim of this study was to investigate whether the use of pre-procedural amiodarone affects: (i) the amount of ablation required to achieve procedural success, and (ii) long-term outcomes. We studied 121 consecutive patients with persistent AF who underwent catheter ablation. The patients were divided into two groups: Group 1, amiodarone (n = 31); Group 2, other antiarrhythmic drugs or rate control (n = 90). All the patients underwent a step-wise ablation procedure beginning with PV isolation, then proceeding with ablation of the CFAEs and linear lesions until sinus rhythm was achieved. Mean left atrial cycle length of AF (AFCL) was recorded at each step. The number of CFAE ablation sites was recorded. The number of CFAE sites in Group 1 was significantly less than that in Group 2 (P = 0.0121). The AFCLs after each step in Group 1 were significantly longer than those in Group 2. The procedure time and the radiofrequency time of CFAE ablation in Group 1 were significantly shorter than that in Group 2 (P = 0.0276 and P = 0.0458, respectively). There was no significant difference between the two groups in early and long-term outcomes. Use of pre-procedural amiodarone prolongs AFCL during catheter ablation and reduces the number of CFAE sites requiring ablation to achieve procedural success while maintaining equivalent long-term results.Keywords
This publication has 19 references indexed in Scilit:
- Electrogram-guided substrate ablation with or without pulmonary vein isolation in patients with persistent atrial fibrillationEP Europace, 2008
- Clinical Outcomes of Catheter Substrate Ablation for High-Risk Patients With Atrial FibrillationJACC, 2008
- HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-UpA report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and Approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society.EP Europace, 2007
- A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrateJACC, 2004
- Fractionation of Electrograms and Linking of Activation During Pharmacologic Cardioversion of Persistent Atrial Fibrillation in the GoatJournal of Cardiovascular Electrophysiology, 2004
- Widening of the Excitable Gap and Enlargement of the Core of Reentry During Atrial Fibrillation With a Pure Sodium Channel Blocker in Canine AtriaCirculation, 2003
- Role of Fibrillation Cycle Length in Spontaneous and Drug-Induced Termination of Human Atrial Fibrillation-Spectral Analysis of Fibrillation Waves From Surface Electrocardiogram-Circulation Journal, 2003
- Widening of the Excitable Gap During Pharmacological Cardioversion of Atrial Fibrillation in the GoatCirculation, 2000
- Electrophysiologic Effects of a Class I Antiarrhythmic Agent, Cibenzoline, on the Refractoriness and Conduction of the Human Atrium In VivoJournal of Cardiovascular Pharmacology, 1996
- Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.Circulation, 1993